Evidence map›Paper›PMID 41023755›Full record

ArticleArthritis research & therapy2025

Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort.

Francesco Natalucci, Clément Triaille, Emilie Sapart, Stéphanie Dierckx, Cécile Van Mullem, Stéphanie De Montjoye, Tatiana Sokolova, Alexandra Avramovska, Patrick Durez

Abstract read
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesco NatalucciPôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Clément TriaillePôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Emilie SapartPôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Stéphanie DierckxCliniques Universitaires Saint-Luc -Rheumatology department, Brussels, Belgium.
Cécile Van MullemCliniques Universitaires Saint-Luc -Rheumatology department, Brussels, Belgium.
Stéphanie De MontjoyeCliniques Universitaires Saint-Luc -Rheumatology department, Brussels, Belgium.
Tatiana SokolovaPôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Alexandra AvramovskaCliniques Universitaires Saint-Luc -Rheumatology department, Brussels, Belgium.
Patrick DurezPôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium. patrick.durez@saintluc.uclouvain.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite an increasing number of targeted and biological disease-modifying anti-rheumatic drugs (ts or bDMARDs), a significant number of Rheumatoid Arthritis (RA) patients are refractory to multiple lines of treatments. The definition of Difficult-to-treat (D2T) RA patients has been proposed to harmonize research on this condition. While data on D2T in established RA are emerging, this is the first study to specifically address the evolution from early disease (ERA) to D2T-RA. To identify early clinical, laboratory, and radiographic predictors of progression from early rheumatoid arthritis to difficult-to-treat RA over a five-year follow-up.

methodsThis was a retrospective monocentric cohort study of DMARD-naïve ERA patients (symptom duration ≤ 12 months), enrolled between 2010 and 2019. Patients were followed for 5 years with data collection at baseline, 6, 12, 36, and 60 months. The primary outcome was the development of D2T-RA, defined according to EULAR 2021 criteria. Baseline analyzed variables included clinical features, serology, radiographic damage, disease activity scores, patient-reported outcomes (PROs) and demographic features. Associations between baseline variables and D2T status were evaluated using univariate and multivariate logistic regression analyses.

resultsWe included 391 ERA patients [M/F 109/282, median age 48.2 years IQR (21.26)]. After 5 years, forty-one patients (10.5%) matched the D2T definition. A higher baseline radiographic damage, seropositivity, and baseline disease activity characterized these patients. Only radiographic damage was confirmed as an independent factor for progression to D2T-RA in a multivariate analysis [OR = 2.38 CI (1.09-5.54); p = 0.03]. During the follow-up, disease activity was consistently higher in the D2T group. D2T patients were exposed to a higher dose of glucocorticoids and more commonly suffered from infections and osteoporosis.

conclusionsBaseline radiographic damage, seropositivity, and high disease activity represent the major risk factors for the evolution from ERA to D2T-RA. Disease activity indices were consistently higher in D2T patients all along the five-year follow-up. In addition, D2T patients received higher GC doses and more commonly developed disease and treatment-related comorbidities.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDisease ProgressionSeverity of Illness IndexAdultAgedBelgiumFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMaleMiddle AgedRadiographyRetrospective StudiesAntirheumatic AgentsD2T-RADifficult to treat rheumatoid arthritisEarly-RAPredictorsRadiographic damageRheumatoid Arthritis

Identifiers

PMID41023755
PMCPMC12482167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.